Oxford BioMedica PLC (OXBDF)

[marcusl2]

“Any new therapy is going to start in refractory patients. [Although] we can get responses in completely refractory patients, it will likely be better if you can do this at an earlier time,” said Maloney, medical director of cellular immunotherapy at Fred Hutchinson Cancer Research Center and a professor of medicine at the University of Washington. “We’re going to see these start moving to a place where we think about them before people have failed several lines of salvage.”

https://www.targetedonc.com/publications/targeted-therapy-news/2018/September-2018/the-impact-of-car-tcell-therapies-in-dlbcl